Lv1
60 积分 2024-03-11 加入
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
1天前
待确认
Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system
1个月前
已完结
Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China
1个月前
已完结
Immune checkpoint inhibitor combinations for patients with advanced endometrial cancer: a network meta-analysis and costutility analysis
4个月前
已关闭
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
5个月前
已完结
Nationwide gastric cancer prevention in China, 2021–2035: a decision analysis on effect, affordability and cost-effectiveness optimisation
1年前
已完结
Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer
1年前
已完结
Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer
1年前
已完结
Cost-Effectiveness Analysis: Selective Use of Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer
1年前
已完结
Cost-Effectiveness of Adjuvant Chemotherapy in the Treatment of Early-Stage Colon Cancer
1年前
已完结
皖公网安备34019202002308
